Precision BioSciences, Inc. (NASDAQ:DTIL) Director Buys $17,225.00 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno J. Germano purchased 3,250 shares of the stock in a transaction dated Tuesday, March 25th. The stock was acquired at an average cost of $5.30 per share, for a total transaction of $17,225.00. Following the completion of the transaction, the director now owns 11,057 shares of the company’s stock, valued at $58,602.10. The trade was a 41.63 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Precision BioSciences Stock Performance

Shares of NASDAQ DTIL opened at $4.70 on Friday. The firm has a market capitalization of $36.05 million, a price-to-earnings ratio of 78.35 and a beta of 1.59. Precision BioSciences, Inc. has a one year low of $3.61 and a one year high of $15.97. The business has a fifty day simple moving average of $5.11 and a 200 day simple moving average of $6.53. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34.

Precision BioSciences (NASDAQ:DTIL) last released its quarterly earnings data on Wednesday, March 26th. The company reported ($3.20) EPS for the quarter, missing analysts’ consensus estimates of ($2.09) by ($1.11). Precision BioSciences had a negative return on equity of 23.69% and a net margin of 11.48%. The business had revenue of $3.47 million for the quarter, compared to the consensus estimate of $4.28 million. Sell-side analysts expect that Precision BioSciences, Inc. will post -1.23 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DTIL. Lynx1 Capital Management LP bought a new stake in shares of Precision BioSciences in the 4th quarter valued at approximately $2,919,000. Janus Henderson Group PLC grew its position in Precision BioSciences by 10.9% in the third quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock valued at $6,322,000 after acquiring an additional 68,943 shares during the period. Citadel Advisors LLC raised its stake in Precision BioSciences by 58.0% during the fourth quarter. Citadel Advisors LLC now owns 153,675 shares of the company’s stock worth $586,000 after acquiring an additional 56,400 shares in the last quarter. Moloney Securities Asset Management LLC raised its stake in Precision BioSciences by 177.0% during the fourth quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company’s stock worth $335,000 after acquiring an additional 56,100 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in shares of Precision BioSciences during the fourth quarter valued at $211,000. Institutional investors own 37.99% of the company’s stock.

Analyst Ratings Changes

DTIL has been the topic of a number of research analyst reports. BMO Capital Markets raised Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 target price on the stock in a report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a research report on Friday.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.